Journal article
Trial of Deferiprone in Parkinson's Disease
D Devos, J Labreuche, O Rascol, JC Corvol, A Duhamel, PG Delannoy, W Poewe, Y Compta, N Pavese, E Ruzička, P Dušek, B Post, BR Bloem, D Berg, W Maetzler, M Otto, MO Habert, S Lehericy, J Ferreira, R Dodel Show all
New England Journal of Medicine | Published : 2022
Abstract
Background Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson's disease, but its effects on disease progression are unclear. Methods We conducted a multicenter, phase 2, randomized, double-blind trial involving participants with newly diagnosed Parkinson's disease who had never received levodopa. Participants were assigned (in a 1:1 ratio) to receive oral deferiprone at a dose of 15 mg per kilogram of body weight twice daily or matched placebo for 36 weeks. Dopaminergic therapy ..
View full abstractGrants
Awarded by Horizon 2020
Funding Acknowledgements
Supported by a grant (633190) from the European Union Horizon 2020 research and innovation program to the FAIR PARK II project.